Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 10/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | SOD1 | P00441 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18587804 | 0.86 | MAOB (0.49) | MAOBRAB9AHTTL3MBTL1ALDH1A1 | |
| SCHEMBL10534532 | 0.86 | PDK2 (0.45) | MAOBALDH1A1LMNACYP3A4 | |
| SCHEMBL31173236 | 0.85 | MAOB (0.51) | MAOBRAB9AHTTL3MBTL1ALDH1A1 | |
| SCHEMBL27075523 | 0.85 | MAOB (0.51) | MAOBRAB9AHTTL3MBTL1ALDH1A1 | |
| SCHEMBL19384427 | 0.85 | MAOB (0.51) | MAOBRAB9AHTTL3MBTL1ALDH1A1 | |
| SCHEMBL19384488 | 0.84 | MAOB (0.50) | MAOBRAB9AHTTL3MBTL1ALDH1A1 | |
| SCHEMBL16256459 | 0.84 | MAOB (0.50) | MAOBRAB9AHTTL3MBTL1ALDH1A1 | |
| SCHEMBL23363616 | 0.82 | MAOB (0.49) | MAOBRAB9AHTTL3MBTL1ALDH1A1 | |
| SCHEMBL16256451 | 0.82 | MAOB (0.49) | MAOBRAB9AHTTL3MBTL1ALDH1A1 | |
| SCHEMBL14241249 | 0.82 | MAOB (0.49) | MAOBRAB9AHTTL3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3681864-A1 | MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE | AbbVie Overseas S.à r.l. (LU) | 2020-07-22 | — | — | EP | disclosed |
| WO-2019053634-A1 | MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE | AbbVie S.à.r.l. (LU) | 2019-03-21 | — | — | WO | disclosed |
| EP-3044216-A2 | NOVEL AND SPECIFIC INHIBITORS OF CYTOCHROME P450 26 RETINOIC ACID HYDROXYLASE | University of Washington through its Center for Commercialization (US) | 2016-07-20 | — | — | EP | disclosed |
| US-9233996-B2 | Multi-metallic organometallic complexes, and related polymers, compositions, methods and systems | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2016-01-12 | — | — | US | disclosed |
| EP-2917200-A1 | ARYL DERIVATIVES AND USES THEREOF | Jacobus Pharmaceutical Company, Inc. (US) | 2015-09-16 | — | — | EP | disclosed |
| WO-2015026990-A2 | NOVEL AND SPECIFIC INHIBITORS OF CYTOCHROME P450 26 RETINOIC ACID HYDROLASE | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2015-02-26 | — | — | WO | disclosed |
| WO-2014074778-A1 | ARYL DERIVATIVES AND USES THEREOF | JACOBUS PHARMACEUTICAL COMPANY, INC. (US) | 2014-05-15 | — | — | WO | disclosed |
| US-20130066029-A1 | MULTI-METALLIC ORGANOMETALLIC COMPLEXES, AND RELATED POLYMERS, COMPOSITIONS, METHODS AND SYSTEMS | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2013-03-14 | — | — | US | disclosed |
| US-8293715-B2 | 10a-Azalide compound crosslinked at 10a- and 12-positions | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-10-23 | — | — | US | disclosed |
| US-20110237784-A1 | 10A-AZALIDE COMPOUND CROSSLINKED AT 10A- AND 12-POSITIONS | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-09-29 | — | — | US | disclosed |
| EP-2155183-A1 | AMINO ACID DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | Neuromed Pharmaceuticals Ltd. (CA) | 2010-02-24 | — | — | EP | disclosed |
| US-20090325964-A1 | Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression | WYETH (US) | 2009-12-31 | — | — | US | disclosed |
| WO-2009005460-A1 | SMALL MOLECULE INHIBITORS OF NAVL.7 SODIUM CHANNELS FOR THE TREATMENT OF PAIN DISORDERS | ASTRAZENECA AB (SE) | 2009-01-08 | — | — | WO | disclosed |
| WO-2009005459-A1 | PHENYL-1,2, 3,4-TETRAHYDROISOQUINOLINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF A PAIN DISORDER | ASTRAZENECA AB (SE) | 2009-01-08 | — | — | WO | disclosed |
| WO-2008141446-A1 | AMINO ACID DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2008-11-27 | — | — | WO | disclosed |
| US-20080262226-A1 | METHODS OF MAKING COMPOUNDS HAVING A BETA-ADRENERGIC INHIBITOR AND A LINKER AND METHODS OF MAKING COMPOUNDS HAVING A BETA-ADRENERGIC INHIBITOR, A LINKER AND A PHOSPHODIESTERASE INHIBITOR | ARTESIAN THERAPEUTICS, INC. (CA) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237784-A1 | 10A-AZALIDE COMPOUND CROSSLINKED AT 10A- AND 12-POSITIONS | DCLRE1A, AZI2, CHD9 | MAOB 1381/4885RAB9A 58/4885HTT 1110/4885 |
| US-20130066029-A1 | MULTI-METALLIC ORGANOMETALLIC COMPLEXES, AND RELATED POLYMERS, COMPOSITIONS, METHODS AND SYSTEMS | PUF60, PICALM, PCBP1 | MAOB 1310/4885RAB9A 4421/4885HTT 2392/4885 |
| US-20090325964-A1 | Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression | GRM5, GRIK5, GRM1 | MAOB 3224/4885RAB9A 1695/4885HTT 1727/4885 |
| US-20080262226-A1 | METHODS OF MAKING COMPOUNDS HAVING A BETA-ADRENERGIC INHIBITOR AND A LINKER AND METHODS OF MAKING COMPOUNDS HAVING A BETA-ADRENERGIC INHIBITOR, A LINKER AND A PHOSPHODIESTERASE INHIBITOR | ADRB2, ADRB3, ADRB1 | MAOB 18/4885RAB9A 1742/4885HTT 4248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.